NCT05346419View on ClinicalTrials.gov

Antiresorptive Effect of Treatment With Risedronate and Vitamin D in Postmenopausal Patients

NACompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

February 3, 2022

Study Completion Date

February 26, 2022

Conditions
Postmenopausal OsteoporosisHypovitaminosis DHyperparathyroidism
Interventions
DRUG

Risedronate

Participants received risedronate 35 mg once a week for 6 months.

DRUG

Vitamin D

Participants received 2,800 IU of vitamin D once a week, with additional daily supplementation of 4,000 IU of vitamin D

Trial Locations (1)

07300

Peri-postmenopause and bone metabolism clinic. Regional Hospital October 1st ISSSTE, Mexico City

All Listed Sponsors
collaborator

National Polytechnic Institute, Mexico

OTHER

collaborator

Universidad Nacional Autonoma de Mexico

OTHER

lead

Hospital Regional 1o de Octubre

OTHER